SEC Form 4 · accession 0001179110-16-029555
CATABASIS PHARMACEUTICALS INC · CATB
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
A later amendment supersedes this filing — read the amendment. The figures below are kept as originally reported (version chain, not an overwrite).
Reporting owner
Joanne M. Donovan
Officer — CMO; SVP Clinical Development
Period of report
Sep 8, 2016
Accepted (ET)
Sep 12, 2016 · 4:17 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001454789
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $4.30 | Sep 8, 2016 | A | 45,000 | A | — | Sep 7, 2026 | Common Stock | 45,000 | 45,000 | D |
Explanation of responses
- F1This option was granted on September 8, 2016 and is subject to vesting over a four year period, with 25% of the shares vesting on the first anniversary of the date of grant and the remainder vesting over the ensuing three years at a rate of 2.0833% per month.